All In Biotech

Drug Trial Radar · NCT04597008

Topical Antibiotic Therapy to Reduce Infection After Operative Treatment of Fractures at High Risk of Infection: TOBRA

Topical Antibiotic Therapy to Reduce Infection After Operative Treatment of Fractures at High Risk of Infection: TOBRA - A Multicenter Randomized Controlled Trial

Last checked: Nov 19, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,660 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,660

Actual

Start

Jun 18, 2021

Primary completion

Jul 30, 2025

Study completion Jul 30, 2025

Sponsor

Lead sponsor
Major Extremity Trauma Research ConsortiumAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
United States Department of Defense
First posted
Oct 22, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The overall objective is to compare the effect of Vancomycin and Tobramycin powder combined (treatment) to Vancomycin powder (control) in the reduction of post-fixation infections of tibial plateau and tibial pilon fractures at high risk of infection (collectively considered the "study injuries").

Conditions

  • Post Operative Surgical Site Infection

Interventions

  • Treatment groupDrug

    Standard of Care + Local Vancomycin + Local Tobramycin: Participants in the treatment group will receive a dose of 1000mg of Vancomycin powder AND a dose of 1200mg of Tobramycin powder in their wound bed, which is placed right before wound closure at the final stafe of definitive fracture fixation.

  • Control groupDrug

    Standard of Care + Local Vancomycin: Participants in the control group will receive a dose of 1000mg of Vancomycin powder in their wound bed, which is placed right before wound closure at the final stage of definitive fracture fixation.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Deep Surgical Site Infection (SSI)Time frame: within 182 days of definitive fracture fixation surgery

Locations

41 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama Heersink School of Medicine

    Birmingham, Alabama

  • Keck School of Medicine of USC

    Los Angeles, California

  • Stanford University

    Redwood City, California

  • _University of California, San Francisco

    San Francisco, California

  • Cedars Sinai

    West Hollywood, California

  • University of Colorado Anschutz Medical Campus

    Aurora, Colorado

  • St Mary's University/Tenent Health

    West Palm Beach, Florida

  • Loyola University Chicago

    Chicago, Illinois

  • Indiana University School of Medicine - Methodist Hospital

    Indianapolis, Indiana

  • Indiana University/Eskenazi Health

    Indianapolis, Indiana

  • University of Kentucky

    Lexington, Kentucky

  • LSU Health Sciences

    New Orleans, Louisiana

  • University of Maryland Shock Trauma Center

    Baltimore, Maryland

  • University of Maryland Shock Trauma/Capitol Regions

    Baltimore, Maryland

  • Harvard/Mass General/Brigham Hospitals

    Boston, Massachusetts

  • Core Well Health

    Grand Rapids, Michigan

  • Hennepin County Medical Center

    Minneapolis, Minnesota

  • University of Mississippi Medical Center

    Jackson, Mississippi

  • Dartmouth Hitchcock

    Lebanon, New Hampshire

  • New York Presbyterian/Hospital for Special Surgery

    New York, New York

  • Jamaica Hospital Medical Center

    Queens, New York

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina

  • Carolinas Medical Center/Atrium Health Musculoskeletal Health Institute

    Charlotte, North Carolina

  • Atrium Health Wake Forest Baptist

    Winston-Salem, North Carolina

  • METROHealth

    Cleveland, Ohio

  • Ohio State University Wexner Medical Center

    Columbus, Ohio

  • University of Oklahoma College of Medicine

    Oklahoma City, Oklahoma

  • Penn State College of Medicine

    Hershey, Pennsylvania

  • University of Pennsylvania Perelman School of Medicine

    Philadelphia, Pennsylvania

  • Temple University

    Philadelphia, Pennsylvania

  • Rhode Island Hospital/Brown University

    Providence, Rhode Island

  • Medical University of South Carolina -

    Charleston, South Carolina

  • Vanderbilt University

    Nashville, Tennessee

  • Baylor Scott & White Research Institute

    Dallas, Texas

  • UTHealth/McGovern Medical School

    Houston, Texas

  • UT Health San Antonio

    San Antonio, Texas

  • University of Utah

    Salt Lake City, Utah

  • University of Virginia

    Charlottesville, Virginia

  • Inova Fairfax MEdical Campus

    Falls Church, Virginia

  • Virginia Commonwealth University Medical Center

    Richmond, Virginia

Showing 40 of 41 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.